ELICIO

Elicio is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes ... Elicio's core business is the development of therapeutic cancer vaccines. ELI-002, its lead clinical program, is designed to stimulate an immune response against the seven Kirsten rat sarcoma (KRAS) mutations driving 25% of solid tumors. ELI-002 is currently being studied in AMPLIFY-201, a Phase 1 dose escalation study, and AMPLIFY-7P, a Phase 1/2 study... Elicio ground-breaking Amphiphile technology is engineering potent vaccines and immunotherapies to defeat an array of aggressive cancers.

Also known as: Elicio Therapeutics, Elicio Therapeutics Inc.

Primary location: Boston United States